Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...
Serious adverse events occurred in 19.1% of fenebrutinib patients versus 18.9% with Ocrevus, leading to withdrawals. Credit: New Africa / Shutterstock.com. Roche’s Genentech has reported new data from ...
Fenebrutinib matched Ocrevus in reducing disability progression in PPMS. This oral treatment significantly slowed disability progression in a Phase 3 trial. Genentech plans to seek approval for ...
Swiss pharma giant Roche (ROG: SIX) has announced new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib met its ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...
BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche (ROG.S), opens new tab said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results